Breaking News
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Sanofi's Meta-analysis Shows No Increased Cancer Risk For Lantus Users

12/8/2011 12:45 AM ET

French drug maker Sanofi (SNY: Quote) on Wednesday announced that a new meta-analysis on the relationship between diabetes and cancer risk demonstrates no increased risk in people using its insulin Lantus (insulin glargine). The company presented the new meta-analysis data reinforcing safety profile of Lantus at the World Diabetes Congress in Dubai.

Lantus is the world's top- selling insulin with $4.7 billion in annual revenue.

Earlier, a study presented at the San Antonio Breast Cancer Symposium reportedly showed that Lantus more than doubled the risk of developing cancer among people with diabetes. The researchers, who examined medical records of 23,266 patients in southern Sweden, were unable to identify the types of most common cancer among Lantus users.

Sanofi noted that the analysis of all its published studies, from more than 80,000 patients enrolled in clinical trials and 38 million patient years of treatment exposure to Lantus, further expand the evidence base on the safety.

Peter Boyle, the study Principal Investigator and President of the International Prevention Research Institute (IPRI), Lyon, France, said, "In the context of all available information, the current evidence supports that insulin glargine is associated with no increased risk of cancer as compared to other insulin therapies. These findings are reassuring for patients and their physicians."

Sanofi pointed out that the meta-analysis on observational studies derived from databases as well as from randomized controlled clinical trials. Also, a case-control study in numerous countries, such as Sweden, Germany, Scotland, England and Taiwan, assessed the risk for cancer in individuals with diabetes using different insulins.

Sanofi further said that independent investigators are currently conducting three large studies, sponsored by the company, to find out any association between cancer and insulin use and to assess if there is any difference in risk between insulin glargine and other insulins. These include two retrospective cohort studies and one case-control study.

Final results of the first study based on Nordic databases will be communicated to regulatory agencies by the end of 2011 and scientific presentations are expected to follow in 2012.

In Paris, Sanofi shares closed Wednesday's trading at 52.84 euros, up 1.03 euros or 1.99 percent. SNY closed at $35.60, up $0.60 or 1.71 percent.

Register
To receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. said Tuesday after the markets closed that its first quarter profit fell 5% from last year, hurt mainly by higher income tax expenses even as revenue grew slightly. The company's quarterly earnings per share came in above analysts' expectations, but its quarterly revenue fell shy of analysts' forecast. With traders digesting a mixed batch of catalysts, stocks saw considerable volatility over the course of the trading day on Tuesday before closing mostly higher. The gains on the day extended the recovery off the two-month lows set last Friday. The major averages showed a notable rebound in afternoon trading to end the day in positive territory. U.S. President Barack Obama and his Russian counterpart Vladimir Putin spoke regarding the ongoing crisis in Ukraine for the first time in over two weeks on Monday, although the two leaders remain far apart on the cause of escalating tensions.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.